Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer

Bioconjugate Chemistry

Volumn 24, Issue 2, 2013, Pages 196-204

  Pressly, Eric D ^a   Pierce, Richard A ^c   Connal, Luke A ^a   Hawker, Craig J ^a,b   Liu, Yongjian ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of California   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MEMBRANES; COPPER COMPOUNDS; DISEASES; MODULAR CONSTRUCTION; PEPTIDES; POSITRON EMISSION TOMOGRAPHY; SYNTHESIS (CHEMICAL); TUMORS;

ANTICANCER EFFECTS; ATRIAL NATRIURETIC PEPTIDES; CT IMAGING; IN-VIVO; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDES; NON-TARGETED; PROSTATE CANCERS; TOMOGRAPHY IMAGING;

NANOPARTICLES;

C ATRIAL NATRIURETIC FACTOR; COPPER 64; GADOTERIC ACID; NANOPARTICLE; NATRIURETIC PEPTIDE RECEPTOR C; POLY(ETHYLENE GLYCOL)METHYL ETHER METHACRYLATE; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SPECIFICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY;

EID: 84874080659     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc300473x     Document Type: Article

References (44)

1. Siegel, R., Naishadham, D., and Jemal, A. (2012) Cancer statistics, 2012 CA Cancer J. Clin. 62, 10-29
2. Turkbey, B., Pinto, P. A., and Choyke, P. L. (2009) Imaging techniques for prostate cancer: implications for focal therapy Nat. Rev. Urol. 6, 191-203
3. Pinto, F., Totaro, A., Palermo, G., Calarco, A., Sacco, E., D'Addessi, A., Racioppi, M., Valentini, A., Gui, B., and Bassi, P. (2012) Imaging in prostate cancer staging: present role and future perspectives Urol. Int. 88, 125-136
4. Ravizzini, G., Turkbey, B., Kurdziel, K., and Choyke, P. L. (2009) New horizons in prostate cancer imaging Eur. J. Radiol. 70, 212-226
5. Lawrence, E. M., Gnanapragasam, V. J., Priest, A. N., and Sala, E. (2012) The emerging role of diffusion-weighted MRI in prostate cancer management Nat. Rev. Urol. 9, 94-101
6. Bouchelouche, K., Turkbey, B., Choyke, P., and Capala, J. (2010) Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging Curr. Urol. Rep. 11, 180-190
7. Lears, K. A., Ferdani, R., Liang, K., Zheleznyak, A., Andrews, R., Sherman, C. D., Achilefu, S., Anderson, C. J., and Rogers, B. E. (2011) In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer J. Nucl. Med. 52, 470-477
8. Jackson, A. B., Nanda, P. K., Rold, T. L., Sieckman, G. L., Szczodroski, A. F., Hoffman, T. J., Chen, X., and Smith, C. J. (2012) 64Cu-NO2A-RGD-Glu-6- Ahx-BBN(7-14)NH2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer Nucl. Med. Biol. 39, 377-387
9. Graham, M. M. and Menda, Y. (2011) Radiopeptide imaging and therapy in the United States J. Nucl. Med. 52 (Suppl 2) 56S-63S
10. Nanda, P. K., Pandey, U., Bottenus, B. N., Rold, T. L., Sieckman, G. L., Szczodroski, A. F., Hoffman, T. J., and Smith, C. J. (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging Nucl. Med. Biol. 39, 461-471
11. Chen, Y., Pullambhatla, M., Foss, C. A., Byun, Y., Nimmagadda, S., Senthamizhchelvan, S., Sgouros, G., Mease, R. C., and Pomper, M. G. (2011) 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido) -pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer Clin. Cancer Res. 17, 7645-7653
12. Lutje, S., Boerman, O. C., van Rij, C. M., Sedelaar, M., Helfrich, W., Oyen, W. J., and Mulders, P. F. (2012) Prospects in radionuclide imaging of prostate cancer Prostate 72, 1262-1272
13. Craft, J. M., De Silva, R. A., Lears, K. A., Andrews, R., Liang, K., Achilefu, S., and Rogers, B. E. (2012) In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer Nucl. Med. Biol. 39, 609-616
14. Liu, Y. and Welch, M. J. (2012) Nanoparticles labeled with positron emitting nuclides: advantages, methods, and applications Bioconjugate Chem. 23, 671-682
15. Talekar, M., Kendall, J., Denny, W., and Garg, S. (2011) Targeting of nanoparticles in cancer: drug delivery and diagnostics Anticancer Drugs 22, 949-962
16. Kievit, F. M. and Zhang, M. (2011) Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers Adv. Mater. 23, H217-H247
17. Steinmetz, N. F., Ablack, A. L., Hickey, J. L., Ablack, J., Manocha, B., Mymryk, J. S., Luyt, L. G., and Lewis, J. D. (2011) Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors Small 7, 1664-1672
18. Chanda, N., Kattumuri, V., Shukla, R., Zambre, A., Katti, K., Upendran, A., Kulkarni, R. R., Kan, P., Fent, G. M., Casteel, S. W., Smith, C. J., Boote, E., Robertson, J. D., Cutler, C., Lever, J. R., Katti, K. V., and Kannan, R. (2010) Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity Proc. Natl. Acad. Sci. U. S. A. 107, 8760-8765
19. Mendoza-Sanchez, A. N., Ferro-Flores, G., Ocampo-Garcia, B. E., Morales-Avila, E., de, M. R. F., De Leon-Rodriguez, L. M., Santos-Cuevas, C. L., Medina, L. A., Rojas-Calderon, E. L., and Camacho-Lopez, M. A. (2010) Lys3-bombesin conjugated to 99mTc-labelled gold nanoparticles for in vivo gastrin releasing peptide-receptor imaging J Biomed. Nanotechnol. 6, 375-384
20. Becker, A. L., Orlotti, N. I., Folini, M., Cavalieri, F., Zelikin, A. N., Johnston, A. P., Zaffaroni, N., and Caruso, F. (2011) Redox-active polymer microcapsules for the delivery of a survivin-specific siRNA in prostate cancer cells ACS Nano 5, 1335-1344
21. Maack, T. (2006) The broad homeostatic role of natriuretic peptides Arq Bras Endocrinol Metabol 50, 198-207
22. Wang, X., Raulji, P., Mohapatra, S. S., Patel, R., Hellermann, G., Kong, X., Vera, P. L., Meyer-Siegler, K. L., Coppola, D., and Mohapatra, S. (2011) Natriuretic peptide receptor a as a novel target for prostate cancer Mol. Cancer 10, 56-67
23. Sun, Y., Eichelbaum, E. J., Wang, H., and Vesely, D. L. (2007) Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells Anticancer Res. 27, 3813-3818
24. Sun, Y., Eichelbaum, E. J., Lenz, A., Skelton, W. P. t., Wang, H., and Vesely, D. L. (2009) Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ras in human prostate cancer cells Anticancer Res. 29, 1889-1893
25. Kong, X., Wang, X., Xu, W., Behera, S., Hellermann, G., Kumar, A., Lockey, R. F., Mohapatra, S., and Mohapatra, S. S. (2008) Natriuretic peptide receptor a as a novel anticancer target Cancer Res. 68, 249-256
26. Terada, N., Shimizu, Y., Kamba, T., Inoue, T., Maeno, A., Kobayashi, T., Nakamura, E., Kamoto, T., Kanaji, T., Maruyama, T., Mikami, Y., Toda, Y., Matsuoka, T., Okuno, Y., Tsujimoto, G., Narumiya, S., and Ogawa, O. (2010) Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model Cancer Res. 70, 1606-1615
27. Vesely, B. A., Alli, A. A., Song, S. J., Gower, W. R., Jr., Sanchez-Ramos, J., and Vesely, D. L. (2005) Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells Eur. J. Clin. Invest. 35, 700-710
28. Shokeen, M., Pressly, E. D., Hagooly, A., Zheleznyak, A., Ramos, N., Fiamengo, A. L., Welch, M. J., Hawker, C. J., and Anderson, C. J. (2011) Evaluation of multivalent, functional polymeric nanoparticles for imaging applications ACS Nano 5, 738-747
29. Pressly, E. D., Rossin, R., Hagooly, A., Fukukawa, K., Messmore, B. W., Welch, M. J., Wooley, K. L., Lamm, M. S., Hule, R. A., Pochan, D. J., and Hawker, C. J. (2007) Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined (64)Cu-labeled nanoparticles comprised of amphiphilic block graft copolymers Biomacromolecules 8, 3126-3134
30. Nagabhushan, M., Miller, C. M., Pretlow, T. P., Giaconia, J. M., Edgehouse, N. L., Schwartz, S., Kung, H. J., de Vere White, R. W., Gumerlock, P. H., Resnick, M. I., Amini, S. B., and Pretlow, T. G. (1996) CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar Cancer Res. 56, 3042-3046
31. Dyke, J. P., Zakian, K. L., Spees, W. M., Matei, C., Chen, Y., Mao, X., Shungu, D. C., and Koutcher, J. A. (2003) Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging Clin. Cancer Res. 9, 4529-4536
32. Roe, K., Mikalsen, L. T., van der Kogel, A. J., Bussink, J., Lyng, H., Ree, A. H., Marignol, L., and Olsen, D. R. (2012) Vascular responses to radiotherapy and androgendeprivation therapy in experimental prostate cancer Radiat. Oncol. 7, 75
33. Ponde, D. E., Dence, C. S., Oyama, N., Kim, J., Tai, Y. C., Laforest, R., Siegel, B. A., and Welch, M. J. (2007) 18F-fluoroacetate: a potential acetate analog for prostate tumor imaging - in vivo evaluation of 18F-fluoroacetate versus 11C-acetate J. Nucl. Med. 48, 420-428
34. McCarthy, D. W., Shefer, R. E., Klinkowstein, R. E., Bass, L. A., Margeneau, W. H., Cutler, C. S., Anderson, C. J., and Welch, M. J. (1997) Efficient production of high specific activity 64Cu using a biomedical cyclotron Nucl. Med. Biol. 24, 35-43
35. Herrero, P., Kim, J., Sharp, T. L., Engelbach, J. A., Lewis, J. S., Gropler, R. J., and Welch, M. J. (2006) Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET J. Nucl. Med. 47, 477-485
36. Liu, Y., Ibricevic, A., Cohen, J. A., Cohen, J. L., Gunsten, S. P., Frechet, J. M., Walter, M. J., Welch, M. J., and Brody, S. L. (2009) Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics Mol. Pharmaceutics 6, 1891-1902
37. Almutairi, A., Rossin, R., Shokeen, M., Hagooly, A., Ananth, A., Capoccia, B., Guillaudeu, S., Abendschein, D., Anderson, C. J., Welch, M. J., and Frechet, J. M. (2009) Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis Proc. Natl. Acad. Sci. U. S. A. 106, 685-690
38. Liu, Y., Abendschein, D., Woodard, G. E., Rossin, R., McCommis, K., Zheng, J., Welch, M. J., and Woodard, P. K. (2010) Molecular imaging of atherosclerotic plaque with (64)Cu-labeled natriuretic peptide and PET J. Nucl. Med. 51, 85-91
39. Liu, Y., Pressly, E. D., Abendschein, D. R., Hawker, C. J., Woodard, G. E., Woodard, P. K., and Welch, M. J. (2011) Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET J. Nucl. Med. 52, 1956-1963
40. Rogers, B. E., Bigott, H. M., McCarthy, D. W., Della Manna, D., Kim, J., Sharp, T. L., and Welch, M. J. (2003) MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue Bioconjugate Chem. 14, 756-763
41. Ting, G., Chang, C. H., and Wang, H. E. (2009) Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy Anticancer Res. 29, 4107-4118
42. Rubattu, S., Sciarretta, S., Morriello, A., Calvieri, C., Battistoni, A., and Volpe, M. (2010) NPR-C: a component of the natriuretic peptide family with implications in human diseases J. Mol. Med. (Berlin) 88, 889-897
43. Bergers, G. and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3, 401-410
44. Dudley, A. C. (2012) Tumor endothelial cells Cold Spring Harbor Perspect. Med. 2, a006536